Medy-Tox메디톡스
086900 · KOSDAQ · ₩086900 · 메디톡스
₩63,900▼ ₩300 (0.47%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩247B | ₩229B | ₩221B | ₩195B | ₩185B |
| Cost of sales | ₩104B | ₩90B | ₩87B | ₩69B | ₩79B |
| Gross profit | ₩143B | ₩139B | ₩134B | ₩126B | ₩106B |
| Operating income | ₩17B | ₩20B | ₩17B | ₩47B | ₩34B |
| Net income | ₩16B | ₩16B | ₩9.7B | ₩37B | ₩93B |
| Net income to shareholders | ₩17B | ₩17B | ₩9.8B | ₩37B | ₩94B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩582B | ₩615B | ₩612B | ₩596B | ₩578B |
| Current assets | ₩155B | ₩187B | ₩166B | ₩135B | ₩161B |
| Cash and equivalents | ₩49B | ₩46B | ₩33B | ₩21B | ₩72B |
| Total liabilities | ₩127B | ₩144B | ₩137B | ₩163B | ₩174B |
| Current liabilities | ₩105B | ₩118B | ₩127B | ₩135B | ₩108B |
| Borrowings | ₩75B | ₩79B | ₩83B | ₩122B | ₩30B |
| Total equity | ₩454B | ₩471B | ₩474B | ₩434B | ₩404B |
| Shareholders' equity | ₩452B | ₩466B | ₩469B | ₩428B | ₩399B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩61B | ₩37B | ₩14B | ₩26B | ₩20B |
| Capital spending | ₩16B | ₩8.7B | ₩7.7B | ₩9.9B | ₩18B |
| Free cash flow | ₩46B | ₩28B | ₩5.9B | ₩16B | ₩2.5B |
| Dividends paid | ₩8.9B | ₩8.4B | ₩8.4B | ₩8B | ₩0 |
Consolidated where available. Amounts in won.
Also known as: Medy-Tox / 메디톡스 / 086900 / KRX:086900
Source: KRX statistical information